{"id":"W2790809143","doi":"10.1200/jco.2018.36.6_suppl.tps707","title":"A phase 2 trial of lenvatinib 18 mg versus 14 mg once daily (QD) in combination with everolimus (5 mg QD) in renal cell carcinoma (RCC) after 1 prior VEGF-targeted treatment.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Everolimus; Adverse effect; Internal medicine; Clinical endpoint; Tolerability; Regimen; Renal cell carcinoma; Nivolumab; Lenvatinib; Phases of clinical research; Oncology; Urology; Surgery; Randomized controlled trial; Cancer; Clinical trial; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001612807,0.001974952,0.001840722,0.0004400795,0.0003859889,0.001066095,0.001082743,0.001498661,0.006963414],"category_scores_gemma":[0.001149067,0.0007814245,0.001265283,0.0002676811,0.0008267401,0.001122014,0.0003985589,0.00349966,0.001657114],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008404195,"about_ca_system_score_gemma":0.001463182,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006672738,"about_ca_topic_score_gemma":0.00197515,"domain_scores_codex":[0.9995275,0.0002460792,0.00001929187,0.00008185319,0.00004370953,0.00008164784],"domain_scores_gemma":[0.9993455,0.0001085661,0.000166893,0.00004684136,0.00003260385,0.0002995911],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9031522,0.04437121,0.001590274,0.000422165,0.0006331636,0.0001224228,0.0001130185,0.001088267,0.01228714,0.0002384852,0.003609294,0.03237228],"study_design_scores_gemma":[0.8204652,0.1731913,0.002703523,0.00001953501,0.0001748302,0.0001024613,0.00002276203,0.000767817,0.0008416105,0.0001724866,0.00152018,0.00001820614],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9859146,0.001737591,0.0006577795,0.0009955892,0.0004246903,0.00515352,0.001756141,0.0001996956,0.003160342],"genre_scores_gemma":[0.9789773,0.001768159,0.002412725,0.001702161,0.0004015887,0.006223535,0.002978684,0.00005439337,0.005481453],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006963414,"threshold_uncertainty_score":0.02329493,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1251830929051753,"score_gpt":0.4327676949944712,"score_spread":0.3075846020892958,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}